drugset / Trial / NCT03737643
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients
Phase 3
Active not recruiting
1407 enrolled
AstraZeneca
European Network of Gynaecological Oncological Trial Groups (ENGOT) · collabGOG Foundation · collabMyriad Genetic Laboratories, Inc. · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a Phase III randomised, double-blind, multi-centre study to evaluate the efficacy and safety of durvalumab in combination with standard of care platinum based chemotherapy and bevacizumab followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian cancer.
Timeline
- Start
- 2019-01-04
- Primary completion
- 2025-03-17
- Completion
- 2026-12-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | Intravenous |
| Subject | Durvalumab | Monoclonal antibody | — | Intravenous |
| Subject | Olaparib | Small molecule | — | Oral |
| Background | Carboplatin | Small molecule | — | — |
| Background | Paclitaxel | Small molecule | — | — |